Role of beta blockers following percutaneous coronary intervention for acute coronary syndrome
| Autor: | Kah Yong Peck, Martin Sebastian, Stephen J. Duffy, Louise Roberts, Andrew E. Ajani, Diem Dinh, Christopher M. Reid, Ernesto Oqueli, Angela Brennan, Melanie Freeman, Nick Andrianopoulos, David J Clark, Andrew W. Teh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Acute coronary syndrome Victoria medicine.drug_class medicine.medical_treatment Adrenergic beta-Antagonists Risk Assessment Ventricular Function Left Percutaneous Coronary Intervention Risk Factors Cause of Death Internal medicine medicine Humans Registries Myocardial infarction Acute Coronary Syndrome Beta blocker Aged Retrospective Studies Postoperative Care Ejection fraction business.industry Proportional hazards model Percutaneous coronary intervention Stroke Volume Middle Aged medicine.disease Treatment Outcome Heart failure Conventional PCI Cardiology Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Heart. 107:728-733 |
| ISSN: | 1468-201X 1355-6037 |
| Popis: | AimsThere is a paucity of evidence supporting routine beta blocker (BB) use in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). The aim of this study was to evaluate BB use post PCI and its association with mortality. Furthermore, the study aimed to evaluate the association between BB and mortality in the subgroups of patients with left ventricular ejection fraction (LVEF) 50%.MethodsUsing a large PCI registry, data from patients with ACS between January 2005 and June 2017 who were alive at 30 days were analysed. Those patients taking BB at 30 days were compared with those who were not taking BB. The primary outcome was all-cause mortality. The mean follow-up was 5.3±3.5 years.ResultsOf the 17 562 patients, 83.3% were on BB. Mortality was lower in the BB group (13.1% vs 19.5%, p=0.0001). Multivariable Cox proportional hazards model showed that BB use was associated with lower overall mortality (adjusted HR 0.87, 95% CI 0.78 to 0.97, p=0.014). In the subgroup analysis, BB use was associated with reduced mortality in LVEF 50% (adjusted HR 1.03, 95% CI 0.87 to 1.21, p=0.74).ConclusionBB use remains high and is associated with reduced mortality. This reduction in mortality is primarily seen in those with reduced ejection fraction, but not in those with preserved ejection fraction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|